CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction ...

SUNNYVALE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

“Dr. Quyyumi's significant expertise in these trials and inspiring leadership, coupled with the world-class capabilities at Emory University School of Medicine, a leading institution in the ...

For the third straight year, the U.S. News & World Report (USNWR) ranked Emory University’s Nell Hodgson Woodruff School of Nursing master’s program as No. 1. On April 8, USNWR released its rankings ...

“No patient with myeloma should die without seeing a bispecific,” declared Nisha Joseph, MD, associate professor, Department of Hematology and Medical Oncology, Emory School of Medicine.

The trial is assessing the therapy for individuals with ischemic heart failure of minimised ejection fraction.

"It ticks all the boxes of everything we've been looking for," says Avtar Roopra, a neuroscience professor in the UW–Madison School of Medicine and ... University and Emory University tried ...

MONDAY, April 21, 2025 (HealthDay News) — Key labs at the U.S. Centers for Disease Control and Prevention (CDC) have shut ...